Verve Therapeutics (VERV) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation for VERVE-102 for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol, LDL-C. VERVE-102 is the company’s novel, in vivo, investigational base editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving LDL-C. VERVE-102 is currently being tested in the Phase 1b Heart-2 clinical trial, which is designed to evaluate the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease who require additional lowering of LDL-C.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Biotech stocks slide as Marks resignation seen being negative for sector
- BMO says Peter Marks resignation ‘significant negative’ for biotech
- Verve Therapeutics: Buy Rating Driven by FDA Clearance and Strong Market Potential
- Positive Outlook for Verve Therapeutics: Buy Rating Backed by FDA Clearance and Promising Developments
- Positive Outlook for Verve Therapeutics: Buy Rating Driven by Promising VERVE-102 Trial Data and Design Improvements
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue